<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2301">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131204</url>
  </required_header>
  <id_info>
    <org_study_id>R3918-PNH-2022</org_study_id>
    <secondary_id>2020-002761-33</secondary_id>
    <nct_id>NCT05131204</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria</brief_title>
  <acronym>ACCESS 2</acronym>
  <official_title>A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Currently Treated With Eculizumab or Ravulizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is:&#xD;
&#xD;
      To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as&#xD;
      assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in patients with PNH&#xD;
      who switch from eculizumab or ravulizumab therapy versus patients who continue their&#xD;
      eculizumab or ravulizumab therapy&#xD;
&#xD;
      The secondary objectives of the study are to:&#xD;
&#xD;
        -  Evaluate the effect of pozelimab and cemdisiran combination treatment versus anti-C5&#xD;
           standard-of-care treatment (eculizumab or ravulizumab) on the following:&#xD;
&#xD;
             -  Transfusion requirements and transfusion parameters&#xD;
&#xD;
             -  Measures of hemolysis: LDH control, breakthrough hemolysis, and inhibition of CH50&#xD;
&#xD;
             -  Hemoglobin levels&#xD;
&#xD;
             -  Fatigue as assessed by Clinical Outcome Assessments (COAs)&#xD;
&#xD;
             -  Health-related quality of life (HRQoL) as assessed by COAs&#xD;
&#xD;
             -  Safety and tolerability&#xD;
&#xD;
        -  To assess the concentrations of total pozelimab and either total eculizumab or total&#xD;
           ravulizumab in serum and total cemdisiran and total C5 protein in plasma&#xD;
&#xD;
        -  To assess the immunogenicity of pozelimab and cemdisiran&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2022</start_date>
  <completion_date type="Anticipated">September 18, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in lactate dehydrogenase (LDH)</measure>
    <time_frame>From baseline to week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with transfusion avoidance</measure>
    <time_frame>Day 1 through week 36</time_frame>
    <description>Patients who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with transfusion avoidance</measure>
    <time_frame>Week 4 through week 36</time_frame>
    <description>Patients who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with breakthrough hemolysis</measure>
    <time_frame>Day 1 through week 36</time_frame>
    <description>Patients with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with breakthrough hemolysis</measure>
    <time_frame>Week 4 (day 29) through week 36</time_frame>
    <description>Patients with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with hemoglobin stabilization</measure>
    <time_frame>Day 1 through week 36</time_frame>
    <description>Patients who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with hemoglobin stabilization</measure>
    <time_frame>Week 4 (day 29) through week 36</time_frame>
    <description>Patients who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adequate control of LDH</measure>
    <time_frame>Day 1 through week 36</time_frame>
    <description>Proportion of patients with adequate control of LDH as defined in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adequate control of LDH</measure>
    <time_frame>Week 8 (day 57) through week 36</time_frame>
    <description>Proportion of patients with adequate control of LDH as defined in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normalization of LDH</measure>
    <time_frame>Day 1 through week 36</time_frame>
    <description>Proportion of patients with normalization of LDH as defined in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normalization of LDH</measure>
    <time_frame>Week 8 (day 57) through week 36</time_frame>
    <description>Proportion of patients with normalization of LDH as defined in the protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale</measure>
    <time_frame>From baseline to week 36</time_frame>
    <description>The FACIT-Fatigue is a 13 item, self-administered clinical outcome assessment (COA) assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-Fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Function (PF) score on the European organization for research and treatment of cancer quality-of-Life questionnaire Core 30 Items (EORTC-QLQ-C30)</measure>
    <time_frame>From baseline to week 36</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as &quot;not at all&quot; and 4 as &quot;very much.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global health status (GHS)/QoL scale score on the EORTC-QLQ-C30</measure>
    <time_frame>From baseline to week 36</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as &quot;not at all&quot; and 4 as &quot;very much.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of RBCs transfused per protocol algorithm</measure>
    <time_frame>Day 1 through week 36</time_frame>
    <description>Per protocol algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of RBCs transfused per protocol algorithm</measure>
    <time_frame>Week 4 through week 36</time_frame>
    <description>Per protocol algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units of RBCs transfused per protocol algorithm</measure>
    <time_frame>Day 1 through week 36</time_frame>
    <description>Per protocol algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units of RBCs transfused per protocol algorithm</measure>
    <time_frame>Week 4 through week 36</time_frame>
    <description>Per protocol algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin levels</measure>
    <time_frame>From baseline to week 36</time_frame>
    <description>Per protocol algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment emergent serious adverse events (SAEs)</measure>
    <time_frame>Up to 88 weeks</time_frame>
    <description>Treatment period and safety follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest</measure>
    <time_frame>Up to 88 weeks</time_frame>
    <description>Treatment period and safety follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity TEAEs leading to treatment discontinuation</measure>
    <time_frame>Up to 88 weeks</time_frame>
    <description>Treatment period and safety follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total CH50</measure>
    <time_frame>From baseline to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total CH50</measure>
    <time_frame>From baseline to week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of total C5 in plasma</measure>
    <time_frame>Through week 62</time_frame>
    <description>Treatment period and safety follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total pozelimab in serum</measure>
    <time_frame>Through week 62</time_frame>
    <description>Treatment period and safety follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total cemdisiran in plasma</measure>
    <time_frame>Through week 32</time_frame>
    <description>Treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total eculizumab in serum</measure>
    <time_frame>Through week 40</time_frame>
    <description>Treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of total ravulizumab in plasma</measure>
    <time_frame>Through week 44</time_frame>
    <description>Treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab</measure>
    <time_frame>Through week 62</time_frame>
    <description>Treatment period and safety follow up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent ADAs to cemdisiran</measure>
    <time_frame>Through week 62</time_frame>
    <description>Treatment period and safety follow up period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>Pozelimab and Cemdisiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 1:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-C5 standard-of-care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 1:1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemdisiran</intervention_name>
    <description>Administered per protocol</description>
    <arm_group_label>Pozelimab and Cemdisiran</arm_group_label>
    <other_name>ALN-CC5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Administered per protocol</description>
    <arm_group_label>Anti-C5 standard-of-care</arm_group_label>
    <arm_group_label>Pozelimab and Cemdisiran</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pozelimab</intervention_name>
    <description>Administered per protocol</description>
    <arm_group_label>Pozelimab and Cemdisiran</arm_group_label>
    <other_name>REGN3918</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravulizumab</intervention_name>
    <description>Administered per protocol</description>
    <arm_group_label>Anti-C5 standard-of-care</arm_group_label>
    <arm_group_label>Pozelimab and Cemdisiran</arm_group_label>
    <other_name>ALXN1210</other_name>
    <other_name>Ultomiris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of PNH confirmed by a history of high-sensitivity flow cytometry from prior&#xD;
             testing&#xD;
&#xD;
          2. Treated with eculizumab or ravulizumab prior to screening visit as described in the&#xD;
             protocol Note: Biosimilars are not permitted, unless approved by the Sponsor&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a screening LDH &gt;1.5 Ã— ULN who have not taken their C5 inhibitor within&#xD;
             the labeled dose interval at the dose prior to the screening LDH assessment&#xD;
&#xD;
          2. Receipt of an organ transplant, history of bone marrow transplantation or other&#xD;
             hematologic transplant&#xD;
&#xD;
          3. Body weight &lt; 40 kilograms at screening visit&#xD;
&#xD;
          4. Any use of complement inhibitor therapy other than eculizumab or ravulizumab in the 26&#xD;
             weeks prior to the screening visit or planned use during the study with the exception&#xD;
             of study treatments&#xD;
&#xD;
          5. Not meeting meningococcal vaccination requirements for eculizumab or ravulizumab&#xD;
             according to the current local prescribing information (where available) and at a&#xD;
             minimum documentation of meningococcal vaccination within 5 years prior to screening&#xD;
             visit.&#xD;
&#xD;
          6. Any contraindication for receiving Neisseria meningitidis vaccination.&#xD;
&#xD;
          7. Positive for hepatitis B, and/ or hepatitis C as described in the protocol&#xD;
&#xD;
          8. History of cancer within the past 5 years, except for adequately treated basal cell&#xD;
             skin cancer, squamous cell skin cancer, or in situ cervical cancer&#xD;
&#xD;
          9. Participation in another interventional clinical study (except R3918-PNH-2021) or use&#xD;
             of any experimental therapy within 30 days before screening visit or within 5&#xD;
             half-lives of that investigational product, whichever is greater, with the exception&#xD;
             of eculizumab or ravulizumab.&#xD;
&#xD;
         10. Patients with functional or anatomic asplenia&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/ Exclusion Criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eculizumab</mesh_term>
    <mesh_term>Ravulizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

